Showing 1401-1410 of 7140 results for "".
Part 4, 1726 nm lasers: Handling referred patients who are already on different treatment regimens
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24342/Chapter 4 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about handling referred patients who are already on different treatment regimens.Which Probiotic for Which Disease? Part 1
https://practicaldermatology.com/topics/atopic-dermatitis/which-probiotic-for-which-disease-part-1/23550/Enhanced interest in probiotics means clinicians need to pick the best strain for common dermatologic conditions.Canadian Perspective: Drs. Bhatia, Sapijaszko, and Kaufmann
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/canadian-perspective-drs-bhatia-sapijaszko-and-kaufmann/32695/Neal Bhatia, MD, speaks with Canadian Dermatology Association vice president Mariusz Sapijaszko, MD, FAACS, and former American Academy of Dermatology president Mark Kaufmann, MD, about different perspectives on advocacy in dermatology, including the use of patient stories.Efficacy and Safety of Newly Approved Oral Sarecycline for Acne
https://practicaldermatology.com/columns/clinical-focus-1/efficacy-and-safety-of-newly-approved-oral-sarecycline-for-acne/22996/A closer look at the first NCE approved to treat acne in more than a decade.Journal Club: Updated Clinical Practice Guidelines
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-updated-clinical-practice-guidelines/32316/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with new Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, about the updated clinical practice guidelines for atopic dermatitis published in the Journal of Dermatology in December.Saeki H, et alPart 7, 1726 nm lasers: When a patient doesn’t improve: Doctors discuss “pearls” of wisdom
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24345/Chapter 7 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about when a patient doesn’t improve: Doctors discuss “pearls” of wisdom.The State of Private Equity in 2024: Impact on the Practice of Dermatology
https://practicaldermatology.com/columns/practice-management/state-private-equity-2024-impact-practice-dermatology/27173/Physician Growth Partners recently published a white paper, “State of Dermatology Private Equity,” that evaluated market trends, strategies, and more. Practical Dermatology® spoke exclusively with CEO Michael Kroin about how the evolution of private equity is impacting the everyday practitioner andStudy Examines Association Between Childhood BMI and Risk of Developing IMSDs
https://practicaldermatology.com/series/dermwire-tv/study-examines-association-between-childhood-bmi-and-risk-of-developing-imsds/27004/In this week's DermwireTV, a new study examines the relationship between childhood BMI and skin diseases; phase 3 data sheds new light on dupilumab’s effect on inflammatory biomarkers in pediatric AD patients; and the president and CEO of Evolus discusses trends in the injectables market.Biologics in Psoriasis: The Next Generation
https://practicaldermatology.com/topics/psoriasis/biologics-in-psoriasis-the-next-generation/20807/Get familiar with the IL-23 monoclonal antibodies.Vtama Approved for AD in Adults and Children
https://practicaldermatology.com/series/dermwire-tv/vtama-approved-ad-adults-and-children/30079/In this week's DermwireTV, the FDA approves Vtama (tapinarof cream 0.1%) for atopic dermatitis in adults and children; the FDA approves Nemluvio (nemolizumab) for moderate-to-severe AD; and the president of Nuance Medical discusses the acquisition of scar treatment brand, Biocorneum.